Wednesday, July 09, 2014 1:05:45 AM
Recent TBPH News
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 • PR Newswire (US) • 04/10/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:16:00 PM
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:11:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:10:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:08:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:06:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:04:32 AM
- Theravance Biopharma to Participate in an Upcoming Investor Conference • PR Newswire (US) • 02/22/2024 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:12:31 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:00:32 PM
- Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 • PR Newswire (US) • 02/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 11:16:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 11:07:26 AM
- Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) • PR Newswire (US) • 01/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 11:01:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 11:09:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 11:06:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/21/2023 10:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:06:39 PM
- Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors • PR Newswire (US) • 12/21/2023 10:00:00 PM
- Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference • PR Newswire (US) • 12/18/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 11:14:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 11:11:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 11:10:03 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM